Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMethylprednisolone
Identification
- Name
- Methylprednisolone
- Accession Number
- DB00959 (APRD00342)
- Type
- Small Molecule
- Groups
- Approved, Vet Approved
- Description
A prednisolone derivative with similar anti-inflammatory action. [PubChem]
- Structure
Structure for DB00959 (Methylprednisolone)
- Synonyms
- (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- 1-dehydro-6alpha-Methylhydrocortisone
- 1-dehydro-6α-methylhydrocortisone
- 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
- delta(1)-6alpha-Methylhydrocortisone
- Medrate
- Medrone
- Methylprednisolon
- Methylprednisolone
- Methylprednisolonum
- Metilprednisolona
- Solomet
- Urbason
- External IDs
- J3.872E / NSC-19987
- Product Ingredients
Ingredient UNII CAS InChI Key Methylprednisolone aceponate ET54W9J4U2 86401-95-8 DALKLAYLIPSCQL-YPYQNWSCSA-N Methylprednisolone acetate 43502P7F0P 53-36-1 PLBHSZGDDKCEHR-LFYFAGGJSA-N Methylprednisolone sodium succinate LEC9GKY20K 2375-03-3 FQISKWAFAHGMGT-SGJOWKDISA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Depo-Medrol Injection, suspension 80 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue Remedy Repack 2014-09-11 Not applicable US 
Depo-Medrol Injection, suspension 80 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue Dispensing Solutions, Inc. 1959-05-28 Not applicable US Depo-Medrol Injection, suspension 40 mg/mL Intra-articular; Intralesional; Intramuscular; Soft tissue A S Medication Solutions 1959-05-28 2017-06-20 US Depo-Medrol Injection, suspension 40 mg/mL Intra-articular; Intralesional; Intramuscular; Soft tissue Remedy Repack 2017-05-10 Not applicable US Depo-Medrol Injection, suspension 80 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue Pharmacia & Upjohn Inc 1959-05-28 Not applicable US Depo-Medrol Injection, suspension 40 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue A S Medication Solutions 1959-05-28 2017-06-20 US Depo-Medrol Injection, suspension 20 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue Pharmacia & Upjohn Inc 1959-05-28 Not applicable US Depo-Medrol Injection, suspension 40 mg/mL Intralesional; Intramuscular; Intrasynovial; Soft tissue Rebel Distributors 1959-05-28 Not applicable US Depo-Medrol Injection, suspension 40 mg/mL Intra-articular; Intralesional; Intramuscular; Soft tissue Pharmacia & Upjohn Inc 1959-05-28 Not applicable US Depo-Medrol Injection, suspension 40 mg/1 Intramuscular Remedy Repack 2013-04-10 2017-03-16 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End A-methapred Injection, powder, lyophilized, for solution 40 mg/mL Intramuscular; Intravenous Hospira, Inc. 2005-12-20 2016-10-26 US A-methapred Injection, powder, lyophilized, for solution 125 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2005-12-20 2016-10-26 US Methylprednisolone Tablet 4 mg/1 Oral Unit Dose Services 1997-10-31 Not applicable US Methylprednisolone Tablet 4 mg/1 Oral bryant ranch prepack 1997-10-31 Not applicable US Methylprednisolone Tablet 16 mg/1 Oral Kaiser Foundations Hospitals 2012-09-12 Not applicable US Methylprednisolone Tablet 4 mg/1 Oral Remedy Repack 2012-09-05 2017-11-08 US MethylPREDNISolone Tablet 4 mg/1 Oral Avera Mc Kennan Hospital 2015-07-10 Not applicable US MethylPREDNISolone Tablet 4 mg/1 Oral A S Medication Solutions 1998-12-22 2017-06-20 US Methylprednisolone Tablet 4 mg/1 Oral A S Medication Solutions 2016-05-26 2017-06-20 US MethylPREDNISolone Tablet 4 mg/1 Oral Dispensing Solutions, Inc. 1998-12-22 Not applicable US - Unapproved/Other Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Hybrisil Gel 10 mg/g Topical Bio Zone Laboratories, Inc. 2010-05-05 Not applicable US Medroloan II SUIK Injection, suspension 40 mg/mL Intra-articular; Intralesional; Intramuscular; Soft tissue Asclemed Usa, Inc. 1959-05-28 Not applicable US Medroloan SUIK Injection, suspension 40 mg/mL Intra-articular; Intralesional; Intramuscular; Soft tissue Asclemed Usa, Inc. 1959-05-28 Not applicable US - International/Other Brands
- Medrate / Medrol / Medrone / Meprolone / Solomet / Urbason
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Depo-medrol With Lidocaine Methylprednisolone acetate (40 mg) + Lidocaine hydrochloride (10 mg) Solution Intra-articular; Intrabursal Pfizer 1973-12-31 Not applicable Canada 
Medrol Acne Lotion Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Sulfur (50 mg) Lotion Topical Pfizer 1973-12-31 2014-04-04 Canada Methylprednisolone Sodium Succinate for Injection, USP Methylprednisolone (500 mg) + Water (10 ml) Powder, for solution Intramuscular; Intravenous Hospira, Inc. 1998-03-12 Not applicable Canada Methylprednisolone Sodium Succinate for Injection, USP Methylprednisolone (1 g) + Water (20 ml) Powder, for solution Intramuscular; Intravenous Hospira, Inc. 1998-03-12 Not applicable Canada Neo-medrol Methylprednisolone acetate (2.5 mg) + Neomycin sulfate (5 mg) Cream Topical Pfizer 1960-12-31 2006-08-02 Canada Neo-medrol Acne Lotion Methylprednisolone acetate (2.5 mg) + Aluminum chlorohydrate (100 mg) + Neomycin sulfate (2.5 mg) + Sulfur (50 mg) Lotion Topical Pfizer 1965-12-31 Not applicable Canada Physicians EZ Use M-pred Methylprednisolone acetate + Bupivacaine hydrochloride + Povidone-iodine Kit Proficient Rx LP 2013-05-30 Not applicable US Physicians EZ Use M-pred Methylprednisolone acetate + Bupivacaine hydrochloride + Povidone-iodine Kit Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical Asclemed Usa, Inc. 2013-05-30 Not applicable US ReadySharp Anesthetics plus MethylPrednisolone 80 Methylprednisolone acetate + Bupivacaine hydrochloride + Lidocaine hydrochloride Kit Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue Terrain Pharmaceuticals 2015-12-29 Not applicable US ReadySharp-P40 Methylprednisolone acetate + Bupivacaine hydrochloride + Lidocaine hydrochloride Kit Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue Terrain Pharmaceuticals 2015-12-29 Not applicable US - Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Antiemetics
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Autonomic Agents
- Central Nervous System Agents
- Corticosteroids for Systemic Use
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hyperglycemia-Associated Agents
- Immunosuppressive Agents
- Methylprednisolone
- Neuroprotective Agents
- P-glycoprotein/ABCB1 Substrates
- Peripheral Nervous System Agents
- Prednisolone
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Protective Agents
- Steroids
- Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
- UNII
- X4W7ZR7023
- CAS number
- 83-43-2
- Weight
- Average: 374.4706
Monoisotopic: 374.20932407 - Chemical Formula
- C22H30O5
- InChI Key
- VHRSUDSXCMQTMA-PJHHCJLFSA-N
- InChI
- InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
- IUPAC Name
- (1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
- SMILES
- [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
Pharmacology
- Indication
Adjunctive therapy for short-term administration in rheumatoid arthritis.
- Structured Indications
- Acne Rosacea
- Acute Gouty Arthritis
- Adrenal cortical hypofunctions
- Adrenocortical Hyperfunction
- Ankylosing Spondylitis (AS)
- Anterior Segment Inflammation
- Arthritis, Juvenile Rheumatoid
- Aspiration Pneumonitis
- Asthma Bronchial
- Atopic Dermatitis (AD)
- Berylliosis
- Bullous dermatitis herpetiformis
- Bursitis
- Choroiditis
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Conjunctivitis, Seasonal Allergic
- Corneal Inflammation
- Cushing's Syndrome
- Dermatitis, Contact
- Drug hypersensitivity reaction
- Epicondylitis
- Erythroblastopenia
- Hypercalcemia
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Reaction
- Iridocyclitis
- Iritis
- Leukaemia, Acute
- Loeffler's syndrome
- Malignant Lymphomas
- Mycosis Fungoides (MF)
- Ophthalmia, Sympathetic
- Optic Neuritis
- Pemphigus
- Perennial Allergic Rhinitis (PAR)
- Post-traumatic Osteoarthritis
- Regional Enteritis
- Rheumatoid Arthritis
- Sarcoidosis
- Seasonal Allergic Rhinitis (SAR)
- Secondary thrombocytopenia
- Serum Sickness
- Severe Seborrheic Dermatitis
- Stevens Johnson Syndrome
- Synovitis
- Systemic Lupus Erythematosus (SLE)
- Trichinosis
- Tuberculosis
- Tuberculosis Meningitis
- Ulcerative Colitis (UC)
- Uveitis
- Acquired immune hemolytic anemia
- Acute nonspecific tenosynovitis
- Acute rheumatic carditis
- Diffuse posterior uveitis
- Exfoliative erythroderma
- Non-suppurative Thyroiditis
- Severe Psoriasis
- Varicella-zoster virus acute retinal necrosis
- Pharmacodynamics
Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
- Mechanism of action
Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Target Actions Organism AGlucocorticoid receptor agonistHuman - Absorption
Oral bioavailability 80-99%
- Volume of distribution
- Not Available
- Protein binding
78%
- Metabolism
Hepatic
- Route of elimination
- Not Available
- Half life
1-3 hours
- Clearance
- Not Available
- Toxicity
LD50=2000 mg/kg (orally in rat)
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline. Experimental 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methylprednisolone. Investigational Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Methylprednisolone. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Methylprednisolone. Approved Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Methylprednisolone. Approved Acetaminophen The serum concentration of Methylprednisolone can be increased when it is combined with Acetaminophen. Approved Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone. Withdrawn Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Methylprednisolone. Experimental Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Methylprednisolone. Approved Afatinib The serum concentration of Methylprednisolone can be increased when it is combined with Afatinib. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methylprednisolone. Experimental Albendazole The serum concentration of Methylprednisolone can be increased when it is combined with Albendazole. Approved, Vet Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Methylprednisolone. Approved, Withdrawn Aldesleukin Methylprednisolone may decrease the antineoplastic activities of Aldesleukin. Approved Aldosterone The serum concentration of Methylprednisolone can be decreased when it is combined with Aldosterone. Experimental Alectinib The serum concentration of Methylprednisolone can be increased when it is combined with Alectinib. Approved Alfentanil The serum concentration of Methylprednisolone can be increased when it is combined with Alfentanil. Approved, Illicit Algeldrate The bioavailability of Methylprednisolone can be decreased when combined with Algeldrate. Experimental Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Methylprednisolone. Investigational Almagate The bioavailability of Methylprednisolone can be decreased when combined with Almagate. Experimental Almasilate The bioavailability of Methylprednisolone can be decreased when combined with Almasilate. Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Methylprednisolone. Experimental Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone. Approved Aloglutamol The bioavailability of Methylprednisolone can be decreased when combined with Aloglutamol. Experimental Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Methylprednisolone. Experimental Aluminium The bioavailability of Methylprednisolone can be decreased when combined with Aluminium. Approved Aluminium acetoacetate The bioavailability of Methylprednisolone can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Methylprednisolone can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide. Approved Amantadine The serum concentration of Methylprednisolone can be increased when it is combined with Amantadine. Approved Ambenonium The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ambenonium. Approved Aminohippuric acid The serum concentration of Methylprednisolone can be increased when it is combined with Aminohippuric acid. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methylprednisolone. Approved Amiodarone The serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline. Approved Amlodipine The serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine. Approved Amphotericin B Methylprednisolone may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Amprenavir The serum concentration of Methylprednisolone can be decreased when it is combined with Amprenavir. Approved Amsacrine The serum concentration of Methylprednisolone can be increased when it is combined with Amsacrine. Approved Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Methylprednisolone. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Methylprednisolone. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Methylprednisolone. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Methylprednisolone. Approved, Investigational Aprepitant The serum concentration of Methylprednisolone can be increased when it is combined with Aprepitant. Approved, Investigational Astemizole The serum concentration of Methylprednisolone can be increased when it is combined with Astemizole. Approved, Withdrawn Atazanavir The serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Methylprednisolone can be increased when it is combined with Atenolol. Approved Atomoxetine The metabolism of Methylprednisolone can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Atorvastatin. Approved Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Methylprednisolone. Withdrawn Azelastine The serum concentration of Methylprednisolone can be increased when it is combined with Azelastine. Approved Azithromycin The serum concentration of Methylprednisolone can be increased when it is combined with Azithromycin. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methylprednisolone. Investigational Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone. Approved, Investigational BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Methylprednisolone. Investigational Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Methylprednisolone. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Methylprednisolone. Experimental Bendroflumethiazide Methylprednisolone may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Methylprednisolone. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Methylprednisolone. Withdrawn Benzocaine The serum concentration of Methylprednisolone can be increased when it is combined with Benzocaine. Approved Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Methylprednisolone. Approved Bepridil The serum concentration of Methylprednisolone can be increased when it is combined with Bepridil. Approved, Withdrawn Bevacizumab Bevacizumab may increase the cardiotoxic activities of Methylprednisolone. Approved, Investigational Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Methylprednisolone. Experimental Biperiden The serum concentration of Methylprednisolone can be increased when it is combined with Biperiden. Approved Bismuth Subcitrate The bioavailability of Methylprednisolone can be decreased when combined with Bismuth Subcitrate. Approved Bismuth subnitrate The bioavailability of Methylprednisolone can be decreased when combined with Bismuth subnitrate. Experimental Boceprevir The serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir. Withdrawn Bortezomib The metabolism of Methylprednisolone can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Methylprednisolone can be increased when it is combined with Bosutinib. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Methylprednisolone. Approved Bromocriptine The serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Methylprednisolone. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Methylprednisolone. Experimental Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Methylprednisolone. Withdrawn Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Methylprednisolone. Experimental Bumetanide Methylprednisolone may increase the hypokalemic activities of Bumetanide. Approved Buprenorphine The serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The serum concentration of Methylprednisolone can be increased when it is combined with Buspirone. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylprednisolone. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Methylprednisolone. Approved Caffeine The serum concentration of Methylprednisolone can be increased when it is combined with Caffeine. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone. Approved, Nutraceutical Calcium Carbonate The bioavailability of Methylprednisolone can be decreased when combined with Calcium Carbonate. Approved Calcium silicate The bioavailability of Methylprednisolone can be decreased when combined with Calcium silicate. Experimental Canagliflozin The serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin. Approved Candesartan The serum concentration of Methylprednisolone can be increased when it is combined with Candesartan. Approved Capromab pendetide Methylprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Captopril The serum concentration of Methylprednisolone can be increased when it is combined with Captopril. Approved Carbamazepine The serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Methylprednisolone. Experimental Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Methylprednisolone. Experimental Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Methylprednisolone. Approved, Vet Approved, Withdrawn Carvedilol The serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol. Approved, Investigational Caspofungin The serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin. Approved Castanospermine The therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Methylprednisolone. Approved, Investigational Ceritinib The serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Methylprednisolone. Withdrawn Chloroquine The serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine. Approved, Vet Approved Chlorothiazide Methylprednisolone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene. Withdrawn Chlorpromazine The serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine. Approved, Vet Approved Chlorpropamide The serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide. Approved Chlorprothixene The serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene. Approved, Withdrawn Chlorthalidone Methylprednisolone may increase the hypokalemic activities of Chlorthalidone. Approved Cholesterol The serum concentration of Methylprednisolone can be increased when it is combined with Cholesterol. Experimental Cholestyramine Cholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cholic Acid The serum concentration of Methylprednisolone can be decreased when it is combined with Cholic Acid. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Methylprednisolone. Approved Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methylprednisolone. Experimental Cilazapril The serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril. Approved Cimetidine The serum concentration of Methylprednisolone can be decreased when it is combined with Cimetidine. Approved Cinoxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cinoxacin. Approved, Withdrawn Ciprofloxacin The serum concentration of Methylprednisolone can be increased when it is combined with Ciprofloxacin. Approved, Investigational Citalopram The serum concentration of Methylprednisolone can be increased when it is combined with Citalopram. Approved Clarithromycin The serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin. Approved Clemastine The metabolism of Methylprednisolone can be decreased when combined with Clemastine. Approved Clofazimine The serum concentration of Methylprednisolone can be increased when it is combined with Clofazimine. Approved, Investigational Clomipramine The serum concentration of Methylprednisolone can be increased when it is combined with Clomipramine. Approved, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Methylprednisolone. Approved Clotrimazole The metabolism of Methylprednisolone can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat. Approved Colchicine The serum concentration of Methylprednisolone can be increased when it is combined with Colchicine. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colforsin The serum concentration of Methylprednisolone can be increased when it is combined with Colforsin. Experimental Conivaptan The serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan. Approved, Investigational Conjugated estrogens The serum concentration of Methylprednisolone can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone. Approved Coumaphos The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Coumaphos. Vet Approved Crizotinib The metabolism of Methylprednisolone can be decreased when combined with Crizotinib. Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Methylprednisolone. Investigational Cyclopenthiazide Methylprednisolone may increase the hypokalemic activities of Cyclopenthiazide. Experimental Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Methylprednisolone. Approved, Investigational Cyclosporine The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Methylprednisolone. Experimental D-Limonene The risk or severity of adverse effects can be increased when D-Limonene is combined with Methylprednisolone. Investigational Dabrafenib The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib. Approved Daclatasvir The serum concentration of Methylprednisolone can be increased when it is combined with Daclatasvir. Approved Dactinomycin The serum concentration of Methylprednisolone can be increased when it is combined with Dactinomycin. Approved Daidzein The serum concentration of Methylprednisolone can be increased when it is combined with Daidzein. Experimental Darunavir The serum concentration of Methylprednisolone can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Methylprednisolone can be decreased when it is combined with Daunorubicin. Approved Decamethonium The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium. Approved Deferasirox The serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Methylprednisolone can be decreased when combined with Delavirdine. Approved Demecarium The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Demecarium. Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methylprednisolone. Investigational dersalazine The risk or severity of adverse effects can be increased when dersalazine is combined with Methylprednisolone. Investigational Desipramine The serum concentration of Methylprednisolone can be increased when it is combined with Desipramine. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Methylprednisolone. Approved Desloratadine The serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine. Approved, Investigational Dexamethasone The serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dextromethorphan The serum concentration of Methylprednisolone can be increased when it is combined with Dextromethorphan. Approved Dichlorvos The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dichlorvos. Vet Approved Diclofenac The serum concentration of Methylprednisolone can be increased when it is combined with Diclofenac. Approved, Vet Approved Dienestrol The serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol. Approved Diethylstilbestrol The serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Methylprednisolone. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Methylprednisolone. Approved Digoxin Digoxin may decrease the cardiotoxic activities of Methylprednisolone. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methylprednisolone. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methylprednisolone. Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Methylprednisolone. Experimental Dihydroergotamine The metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine. Approved Dihydrotestosterone Methylprednisolone may increase the fluid retaining activities of Dihydrotestosterone. Illicit Diltiazem The metabolism of Methylprednisolone can be decreased when combined with Diltiazem. Approved Dipyridamole The serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole. Approved Distigmine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Distigmine. Experimental Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone. Approved, Investigational Donepezil The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Donepezil. Approved Doxazosin The serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin. Approved Doxepin The serum concentration of Methylprednisolone can be increased when it is combined with Doxepin. Approved Doxorubicin The serum concentration of Methylprednisolone can be decreased when it is combined with Doxorubicin. Approved, Investigational Doxycycline The metabolism of Methylprednisolone can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Methylprednisolone can be increased when it is combined with Dronabinol. Approved, Illicit Dronedarone The metabolism of Methylprednisolone can be decreased when combined with Dronedarone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Methylprednisolone. Approved Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methylprednisolone. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Methylprednisolone. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Methylprednisolone. Investigational Echothiophate The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Edrophonium. Approved Elbasvir The serum concentration of Methylprednisolone can be increased when it is combined with Elbasvir. Approved Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone. Approved Enalapril The serum concentration of Methylprednisolone can be increased when it is combined with Enalapril. Approved, Vet Approved Enasidenib The serum concentration of Methylprednisolone can be increased when it is combined with Enasidenib. Approved Enoxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enoxacin. Approved Enzalutamide The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Methylprednisolone can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Methylprednisolone. Approved Equol The serum concentration of Methylprednisolone can be increased when it is combined with Equol. Investigational Ergonovine The serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Methylprednisolone can be increased when it is combined with Ergotamine. Approved Erythromycin The metabolism of Methylprednisolone can be decreased when combined with Erythromycin. Approved, Vet Approved Estradiol The serum concentration of Methylprednisolone can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estramustine The serum concentration of Methylprednisolone can be increased when it is combined with Estramustine. Approved Estriol The serum concentration of Methylprednisolone can be increased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Methylprednisolone can be increased when it is combined with Estrone. Approved Etacrynic acid Methylprednisolone may increase the hypokalemic activities of Etacrynic acid. Approved Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Methylprednisolone. Experimental Ethinyl Estradiol The serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Methylprednisolone. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Methylprednisolone. Approved Etoposide The serum concentration of Methylprednisolone can be increased when it is combined with Etoposide. Approved Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone. Approved, Investigational Etravirine The serum concentration of Methylprednisolone can be increased when it is combined with Etravirine. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Methylprednisolone. Approved Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Methylprednisolone. Approved, Investigational exisulind The risk or severity of adverse effects can be increased when exisulind is combined with Methylprednisolone. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Methylprednisolone. Experimental Felodipine The serum concentration of Methylprednisolone can be increased when it is combined with Felodipine. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Methylprednisolone. Approved Fentanyl The serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenthion The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Methylprednisolone. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Methylprednisolone. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Methylprednisolone. Experimental Fexofenadine The serum concentration of Methylprednisolone can be increased when it is combined with Fexofenadine. Approved Fidaxomicin The serum concentration of Methylprednisolone can be increased when it is combined with Fidaxomicin. Approved Fingolimod Methylprednisolone may increase the immunosuppressive activities of Fingolimod. Approved, Investigational Fleroxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Methylprednisolone. Approved, Withdrawn Fluconazole The metabolism of Methylprednisolone can be decreased when combined with Fluconazole. Approved Flumequine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Methylprednisolone. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Methylprednisolone. Experimental Fluoxetine The serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine. Approved, Vet Approved Fluoxymesterone Methylprednisolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flupentixol The serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol. Approved, Withdrawn Fluphenazine The serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine. Approved Flurazepam The serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Methylprednisolone. Approved, Investigational Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Methylprednisolone. Approved Fluvoxamine The metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Methylprednisolone can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin. Approved Furosemide Methylprednisolone may increase the hypokalemic activities of Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Methylprednisolone can be increased when it is combined with Fusidic Acid. Approved Galantamine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin. Approved, Investigational Gefitinib The serum concentration of Methylprednisolone can be increased when it is combined with Gefitinib. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Methylprednisolone can be increased when it is combined with Genistein. Investigational Ginkgo biloba The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ginkgo biloba. Approved, Nutraceutical Gitoformate Gitoformate may decrease the cardiotoxic activities of Methylprednisolone. Experimental Glecaprevir The serum concentration of Methylprednisolone can be increased when it is combined with Glecaprevir. Approved Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone. Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Methylprednisolone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone. Approved Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone. Approved GLPG-0492 Methylprednisolone may increase the fluid retaining activities of GLPG-0492. Investigational Glyburide The serum concentration of Methylprednisolone can be increased when it is combined with Glyburide. Approved Glycerin The serum concentration of Methylprednisolone can be increased when it is combined with Glycerin. Approved, Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Methylprednisolone. Approved Gramicidin D The serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Grepafloxacin. Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Methylprednisolone. Experimental Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Methylprednisolone. Investigational Haloperidol The serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol. Approved Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Methylprednisolone. Experimental Hexestrol The serum concentration of Methylprednisolone can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Methylprednisolone. Investigational Huperzine A The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Huperzine A. Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone. Approved, Investigational Hydrochlorothiazide Methylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocortisone The serum concentration of Methylprednisolone can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide Methylprednisolone may increase the hypokalemic activities of Hydroflumethiazide. Approved Hydrotalcite The bioavailability of Methylprednisolone can be decreased when combined with Hydrotalcite. Experimental Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Methylprednisolone. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Methylprednisolone. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Methylprednisolone. Approved Imatinib The metabolism of Methylprednisolone can be decreased when combined with Imatinib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Methylprednisolone. Experimental Imipramine The serum concentration of Methylprednisolone can be increased when it is combined with Imipramine. Approved Indacaterol Indacaterol may increase the hypokalemic activities of Methylprednisolone. Approved Indapamide Methylprednisolone may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Methylprednisolone can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Methylprednisolone. Investigational Indomethacin The serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Methylprednisolone. Withdrawn Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methylprednisolone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methylprednisolone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methylprednisolone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone. Approved Ipidacrine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ipidacrine. Experimental Isavuconazonium The metabolism of Methylprednisolone can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurophate The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate. Approved, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone. Approved Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Methylprednisolone. Withdrawn Isradipine The metabolism of Methylprednisolone can be decreased when combined with Isradipine. Approved Itraconazole The serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Methylprednisolone can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Methylprednisolone can be increased when it is combined with Ivermectin. Approved, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Methylprednisolone. Experimental Ketamine The serum concentration of Methylprednisolone can be increased when it is combined with Ketamine. Approved, Vet Approved Ketoconazole The serum concentration of Methylprednisolone can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Methylprednisolone. Experimental Lansoprazole The serum concentration of Methylprednisolone can be increased when it is combined with Lansoprazole. Approved, Investigational Lapatinib The serum concentration of Methylprednisolone can be increased when it is combined with Lapatinib. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin. Approved, Investigational Levothyroxine The serum concentration of Methylprednisolone can be decreased when it is combined with Levothyroxine. Approved Lidocaine The serum concentration of Methylprednisolone can be increased when it is combined with Lidocaine. Approved, Vet Approved Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone. Approved Liothyronine The serum concentration of Methylprednisolone can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Methylprednisolone can be decreased when it is combined with Liotrix. Approved Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methylprednisolone. Approved Lisinopril The serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone. Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Methylprednisolone. Approved Lomitapide The serum concentration of Methylprednisolone can be increased when it is combined with Lomitapide. Approved Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Methylprednisolone. Experimental Loperamide The serum concentration of Methylprednisolone can be increased when it is combined with Loperamide. Approved Lopinavir The serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir. Approved Loratadine The serum concentration of Methylprednisolone can be increased when it is combined with Loratadine. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone. Approved Losartan The serum concentration of Methylprednisolone can be increased when it is combined with Losartan. Approved Lovastatin The metabolism of Methylprednisolone can be decreased when combined with Lovastatin. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Methylprednisolone. Approved Luliconazole The serum concentration of Methylprednisolone can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Methylprednisolone can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Methylprednisolone. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Methylprednisolone. Illicit, Withdrawn Magaldrate The bioavailability of Methylprednisolone can be decreased when combined with Magaldrate. Withdrawn Magnesium Hydroxide The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Hydroxide. Approved Magnesium oxide The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Methylprednisolone can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Methylprednisolone. Approved Magnesium silicate The bioavailability of Methylprednisolone can be decreased when combined with Magnesium silicate. Experimental Magnesium Trisilicate The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Malathion. Approved, Investigational Maprotiline The serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Methylprednisolone. Approved Mebendazole The serum concentration of Methylprednisolone can be increased when it is combined with Mebendazole. Approved, Vet Approved Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Methylprednisolone. Approved Mefloquine The serum concentration of Methylprednisolone can be increased when it is combined with Mefloquine. Approved Megestrol acetate The serum concentration of Methylprednisolone can be increased when it is combined with Megestrol acetate. Approved, Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Memantine. Approved, Investigational Meprobamate The serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate. Approved, Illicit Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone. Approved Mesterolone Methylprednisolone may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Methylprednisolone can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone. Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Methylprednisolone. Experimental Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone. Approved Methadone The serum concentration of Methylprednisolone can be increased when it is combined with Methadone. Approved Methallenestril The serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Methylprednisolone may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methyl salicylate. Approved, Vet Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methylprednisolone. Approved Methyltestosterone Methylprednisolone may increase the fluid retaining activities of Methyltestosterone. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Methylprednisolone. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Methylprednisolone. Experimental Metoclopramide The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Metoclopramide. Approved, Investigational Metolazone Methylprednisolone may increase the hypokalemic activities of Metolazone. Approved Metoprolol The serum concentration of Methylprednisolone can be increased when it is combined with Metoprolol. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Methylprednisolone. Experimental Mibefradil The serum concentration of Methylprednisolone can be increased when it is combined with Mibefradil. Withdrawn Miconazole The serum concentration of Methylprednisolone can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam. Approved, Illicit Mifepristone The serum concentration of Methylprednisolone can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Methylprednisolone. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Methylprednisolone. Approved Minaprine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methylprednisolone. Approved, Investigational Mitomycin The serum concentration of Methylprednisolone can be increased when it is combined with Mitomycin. Approved Mitotane The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Methylprednisolone can be decreased when it is combined with Mitoxantrone. Approved, Investigational Mivacurium Mivacurium may increase the adverse neuromuscular activities of Methylprednisolone. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Methylprednisolone. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Methylprednisolone. Experimental Morphine The serum concentration of Methylprednisolone can be increased when it is combined with Morphine. Approved, Investigational Moxestrol The serum concentration of Methylprednisolone can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Methylprednisolone. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Methylprednisolone. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nalidixic Acid. Approved Naltrexone The serum concentration of Methylprednisolone can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved Nandrolone Methylprednisolone may increase the fluid retaining activities of Nandrolone. Experimental Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Methylprednisolone. Approved, Vet Approved Naringenin The serum concentration of Methylprednisolone can be increased when it is combined with Naringenin. Experimental Natalizumab The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab. Approved, Investigational Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methylprednisolone. Approved, Investigational Nefazodone The serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nemonoxacin. Investigational Neostigmine The serum concentration of Methylprednisolone can be increased when it is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Methylprednisolone. Approved Netupitant The serum concentration of Methylprednisolone can be increased when it is combined with Netupitant. Approved Nevirapine The serum concentration of Methylprednisolone can be decreased when it is combined with Nevirapine. Approved Nicardipine The serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Methylprednisolone. Approved Nicorandil The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil. Approved Nifedipine The serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine. Approved Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Methylprednisolone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Methylprednisolone. Approved Nilotinib The metabolism of Methylprednisolone can be decreased when combined with Nilotinib. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Methylprednisolone. Approved, Withdrawn Nisoldipine The serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine. Approved Nitrazepam The serum concentration of Methylprednisolone can be increased when it is combined with Nitrazepam. Approved Nitrendipine The serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine. Approved Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methylprednisolone. Investigational Norethisterone The serum concentration of Methylprednisolone can be decreased when it is combined with Norethisterone. Approved Norfloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Norfloxacin. Approved Olaparib The metabolism of Methylprednisolone can be decreased when combined with Olaparib. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Methylprednisolone. Experimental Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Methylprednisolone. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone. Approved Omeprazole The serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Methylprednisolone. Vet Approved Osimertinib The serum concentration of Methylprednisolone can be increased when it is combined with Osimertinib. Approved Ouabain Ouabain may decrease the cardiotoxic activities of Methylprednisolone. Approved Oxandrolone Methylprednisolone may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Oxolinic acid. Experimental Oxymetholone Methylprednisolone may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Methylprednisolone. Withdrawn P-Nitrophenol The serum concentration of Methylprednisolone can be increased when it is combined with P-Nitrophenol. Experimental Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylprednisolone. Approved, Vet Approved Palbociclib The serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib. Approved Palmitic Acid The serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid. Experimental Pantoprazole The serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole. Approved Paraoxon The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Methylprednisolone. Approved Paroxetine The serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Methylprednisolone. Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital. Approved, Vet Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Methylprednisolone. Approved, Vet Approved, Withdrawn Perindopril The serum concentration of Methylprednisolone can be increased when it is combined with Perindopril. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Methylprednisolone. Experimental Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Methylprednisolone. Approved, Withdrawn Phenobarbital The serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Methylprednisolone. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Methylprednisolone. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Methylprednisolone. Approved, Investigational Phenytoin The serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Physostigmine. Approved Pibrentasvir The serum concentration of Methylprednisolone can be increased when it is combined with Pibrentasvir. Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone. Approved, Investigational Pimozide The serum concentration of Methylprednisolone can be increased when it is combined with Pimozide. Approved Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methylprednisolone. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pipemidic acid. Experimental Piretanide Methylprednisolone may increase the hypokalemic activities of Piretanide. Experimental Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Methylprednisolone. Investigational Piromidic acid The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Methylprednisolone. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Methylprednisolone. Approved Platelet Activating Factor The serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor. Experimental Polyestradiol phosphate The serum concentration of Methylprednisolone can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Methylprednisolone may increase the hypokalemic activities of Polythiazide. Approved Ponatinib The serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib. Approved Posaconazole The serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methylprednisolone. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Methylprednisolone. Experimental Pravastatin The serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin. Approved Prazosin The serum concentration of Methylprednisolone can be increased when it is combined with Prazosin. Approved Prednisone The serum concentration of Methylprednisolone can be increased when it is combined with Prednisone. Approved, Vet Approved Primidone The serum concentration of Methylprednisolone can be decreased when it is combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Methylprednisolone can be increased when it is combined with Probenecid. Approved Progesterone The serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Methylprednisolone. Experimental Promestriene The serum concentration of Methylprednisolone can be increased when it is combined with Promestriene. Investigational Promethazine The serum concentration of Methylprednisolone can be increased when it is combined with Promethazine. Approved Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Methylprednisolone. Approved Propafenone The serum concentration of Methylprednisolone can be increased when it is combined with Propafenone. Approved Propranolol The serum concentration of Methylprednisolone can be increased when it is combined with Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Methylprednisolone. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Methylprednisolone. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Methylprednisolone. Experimental Protriptyline The serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline. Approved Prulifloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Methylprednisolone. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pyridostigmine. Approved Quercetin The serum concentration of Methylprednisolone can be increased when it is combined with Quercetin. Experimental Quinacrine The serum concentration of Methylprednisolone can be increased when it is combined with Quinacrine. Approved Quinestrol The serum concentration of Methylprednisolone can be increased when it is combined with Quinestrol. Approved Quinethazone Methylprednisolone may increase the hypokalemic activities of Quinethazone. Approved Quinidine The serum concentration of Methylprednisolone can be increased when it is combined with Quinidine. Approved Quinine The serum concentration of Methylprednisolone can be increased when it is combined with Quinine. Approved Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Methylprednisolone. Approved Ranitidine The serum concentration of Methylprednisolone can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Methylprednisolone can be increased when it is combined with Ranolazine. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Methylprednisolone. Withdrawn Reboxetine The serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine. Approved, Investigational Regorafenib The serum concentration of Methylprednisolone can be increased when it is combined with Regorafenib. Approved Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methylprednisolone. Approved, Investigational Reserpine The serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone. Experimental, Investigational Rifabutin The serum concentration of Methylprednisolone can be decreased when it is combined with Rifabutin. Approved Rifampicin The serum concentration of Methylprednisolone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Methylprednisolone can be decreased when it is combined with Rifapentine. Approved Rilpivirine The serum concentration of Methylprednisolone can be increased when it is combined with Rilpivirine. Approved Ritonavir The serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir. Approved, Investigational Rivastigmine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Methylprednisolone. Investigational, Withdrawn Roflumilast Roflumilast may increase the immunosuppressive activities of Methylprednisolone. Approved Rolapitant The serum concentration of Methylprednisolone can be increased when it is combined with Rolapitant. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methylprednisolone. Approved, Investigational Rosoxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Methylprednisolone. Approved Rufloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Methylprednisolone. Approved, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Methylprednisolone. Approved Saquinavir The serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir. Approved, Investigational Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone. Approved Scopolamine The serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine. Approved Secoisolariciresinol The serum concentration of Methylprednisolone can be increased when it is combined with Secoisolariciresinol. Investigational Selegiline The serum concentration of Methylprednisolone can be increased when it is combined with Selegiline. Approved, Investigational, Vet Approved Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Methylprednisolone. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Methylprednisolone. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Methylprednisolone. Investigational Sertraline The serum concentration of Methylprednisolone can be increased when it is combined with Sertraline. Approved Sildenafil The metabolism of Methylprednisolone can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Methylprednisolone can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Methylprednisolone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Methylprednisolone can be increased when it is combined with Simvastatin. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone. Approved Sirolimus The serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus. Approved, Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sitafloxacin. Experimental Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methylprednisolone. Approved, Investigational Sorafenib The serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib. Approved, Investigational Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methylprednisolone. Investigational Sparfloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sparfloxacin. Approved Spironolactone The serum concentration of Methylprednisolone can be increased when it is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Methylprednisolone. Investigational St. John's Wort The serum concentration of Methylprednisolone can be decreased when it is combined with St. John's Wort. Nutraceutical Stanozolol Methylprednisolone may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Staurosporine The serum concentration of Methylprednisolone can be increased when it is combined with Staurosporine. Experimental Stiripentol The serum concentration of Methylprednisolone can be increased when it is combined with Stiripentol. Approved Streptozocin The serum concentration of Methylprednisolone can be decreased when it is combined with Streptozocin. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methylprednisolone. Approved Sulfinpyrazone The serum concentration of Methylprednisolone can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole The metabolism of Methylprednisolone can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Methylprednisolone. Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone. Approved, Investigational Sumatriptan The serum concentration of Methylprednisolone can be increased when it is combined with Sumatriptan. Approved, Investigational Sunitinib The serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Methylprednisolone. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The serum concentration of Methylprednisolone can be increased when it is combined with Tacrine. Withdrawn Tacrolimus The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone. Approved, Investigational Tamoxifen The serum concentration of Methylprednisolone can be decreased when it is combined with Tamoxifen. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Methylprednisolone. Investigational Taurocholic Acid The serum concentration of Methylprednisolone can be increased when it is combined with Taurocholic Acid. Experimental Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Methylprednisolone. Withdrawn Telithromycin The serum concentration of Methylprednisolone can be increased when it is combined with Telithromycin. Approved Telmisartan The serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan. Approved, Investigational Temafloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Temafloxacin. Withdrawn Temsirolimus The serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus. Approved Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Methylprednisolone. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Methylprednisolone. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Methylprednisolone. Vet Approved Terazosin The serum concentration of Methylprednisolone can be increased when it is combined with Terazosin. Approved Terfenadine The serum concentration of Methylprednisolone can be increased when it is combined with Terfenadine. Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Methylprednisolone. Experimental Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Methylprednisolone. Approved Tesmilifene The serum concentration of Methylprednisolone can be decreased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of Methylprednisolone can be increased when it is combined with Testosterone. Approved, Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Methylprednisolone. Approved Tibolone The serum concentration of Methylprednisolone can be increased when it is combined with Tibolone. Approved Ticagrelor The serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor. Approved Ticlopidine The metabolism of Methylprednisolone can be decreased when combined with Ticlopidine. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Methylprednisolone. Investigational Tocilizumab The serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab. Approved Tofacitinib Methylprednisolone may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone. Approved Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone. Approved Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone. Approved Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Methylprednisolone. Approved Tolvaptan The serum concentration of Methylprednisolone can be increased when it is combined with Tolvaptan. Approved Torasemide Methylprednisolone may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Methylprednisolone. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Methylprednisolone. Approved, Investigational Trazodone The serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Methylprednisolone. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trichlorfon. Vet Approved Trichlormethiazide Methylprednisolone may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Trifluoperazine The serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine. Approved Triflupromazine The serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine. Approved, Vet Approved Trimethoprim The serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim. Approved, Vet Approved Trimipramine The serum concentration of Methylprednisolone can be increased when it is combined with Trimipramine. Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Methylprednisolone. Investigational Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Methylprednisolone. Withdrawn Troleandomycin The serum concentration of Methylprednisolone can be increased when it is combined with Troleandomycin. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trovafloxacin. Approved, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine. Approved Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Methylprednisolone. Experimental Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Methylprednisolone. Investigational, Withdrawn Velpatasvir The serum concentration of Methylprednisolone can be increased when it is combined with Velpatasvir. Approved Venlafaxine The metabolism of Methylprednisolone can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Methylprednisolone can be decreased when combined with Verapamil. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone. Approved, Investigational Vinblastine The serum concentration of Methylprednisolone can be decreased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine. Approved, Investigational Vinorelbine The serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine. Approved, Investigational Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Methylprednisolone. Approved, Investigational Voriconazole The serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole. Approved, Investigational Voxilaprevir The serum concentration of Methylprednisolone can be increased when it is combined with Voxilaprevir. Approved Warfarin Methylprednisolone may increase the anticoagulant activities of Warfarin. Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Methylprednisolone. Approved Zeranol The serum concentration of Methylprednisolone can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Methylprednisolone. Approved, Investigational, Withdrawn Zimelidine The serum concentration of Methylprednisolone can be increased when it is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Methylprednisolone. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, "Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use." U.S. Patent US4587236, issued March, 1973.
US4587236- General References
- Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225]
- External Links
- Human Metabolome Database
- HMDB15094
- KEGG Drug
- D00407
- PubChem Compound
- 6741
- PubChem Substance
- 46504885
- ChemSpider
- 6485
- ChEBI
- 6888
- ChEMBL
- CHEMBL650
- Therapeutic Targets Database
- DAP001040
- PharmGKB
- PA450466
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Methylprednisolone
- ATC Codes
- D07CA02 — Methylprednisolone and antibiotics
- D07CA — Corticosteroids, weak, combinations with antibiotics
- D07C — CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- S01CA — Corticosteroids and antiinfectives in combination
- S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- D07AC — Corticosteroids, potent (group III)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D07AA — Corticosteroids, weak (group I)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D10AA — Corticosteroids, combinations for treatment of acne
- D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE
- D10 — ANTI-ACNE PREPARATIONS
- D — DERMATOLOGICALS
- H02AB — Glucocorticoids
- H02A — CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
- H02 — CORTICOSTEROIDS FOR SYSTEMIC USE
- H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
- AHFS Codes
- 68:04.00
- PDB Entries
- Not Available
- FDA label
- Download (244 KB)
- MSDS
- Download (72.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Pharmacia and upjohn co
- Cadista pharmaceuticals inc
- Duramed pharmaceuticals inc sub barr laboratories inc
- Heather drug co inc
- Par pharmaceutical inc
- Sandoz inc
- Vintage pharmaceuticals inc
- Watson laboratories inc
- Abbott laboratories hosp products div
- Hemopharm usa corp
- Hospira inc
- Elkins sinn div ah robins co inc
- Organon usa inc
- Abraxis pharmaceutical products
- App pharmaceuticals llc
- Bedford laboratories
- International medication systems ltd
- Teva parenteral medicines inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Aidarex Pharmacuticals LLC
- Amerisource Health Services Corp.
- Apotheca Inc.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Barr Pharmaceuticals
- Bedford Labs
- Breckenridge Pharmaceuticals
- Bryant Ranch Prepack
- C.O. Truxton Inc.
- Cadista Pharmaceuticals Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Clint Pharmaceutical Inc.
- DAVA Pharmaceuticals
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DRX Pharmaceuticals
- General Injectables and Vaccines Inc.
- Greenstone LLC
- H.J. Harkins Co. Inc.
- Hemofarm AD
- Hospira Inc.
- Innoviant Pharmacy Inc.
- Keltman Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mckesson Corp.
- Medisca Inc.
- Merrell Pharmaceuticals Inc.
- Neuman Distributors Inc.
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- Patheon Inc.
- PD-Rx Pharmaceuticals Inc.
- Pfizer Inc.
- Pharmacia Inc.
- Pharmedix
- Physician Partners Ltd.
- Physicians Total Care Inc.
- Prasco Labs
- Preferred Pharmaceuticals Inc.
- Prescript Pharmaceuticals
- Qualitest
- Rebel Distributors Corp.
- Redpharm Drug
- San Jose Surgical Supply Inc.
- Sandhills Packaging Inc.
- Sandoz
- Schein Pharmaceutical Inc.
- Sicor Pharmaceuticals
- Southwood Pharmaceuticals
- Spectrum Pharmaceuticals
- Stat Rx Usa
- Vintage Pharmaceuticals Inc.
- Dosage forms
Form Route Strength Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/2mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/mL Injection, suspension Intralesional; Intramuscular; Intrasynovial; Soft tissue 20 mg/mL Injection, suspension Intralesional; Intramuscular; Intrasynovial; Soft tissue 40 mg/mL Injection, suspension Intralesional; Intramuscular; Intrasynovial; Soft tissue 80 mg/mL Injection, suspension Intramuscular 40 mg/1 Suspension Intra-articular; Intralesional; Intramuscular; Intrasynovial 20 mg Suspension Intra-articular; Intralesional; Intramuscular; Intrasynovial 80 mg Suspension Intra-articular; Intralesional; Intramuscular; Intrasynovial 40 mg Solution Intra-articular; Intrabursal Gel Topical 10 mg/g Tablet Oral 2 mg/1 Tablet Oral 32 mg/1 Tablet Oral 16 mg Tablet Oral 4 mg Cream Topical 2.5 mg Tablet Oral 16 mg/1 Tablet Oral 4 mg/1 Tablet Oral 8 mg/1 Injection, suspension Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue 40 mg/mL Injection, suspension Intra-articular; Intralesional; Intramuscular; Parenteral; Soft tissue 80 mg/mL Injection, suspension Intra-articular; Intralesional; Intramuscular; Soft tissue 40 mg/mL Injection, suspension Intra-articular; Intralesional; Intramuscular; Soft tissue 80 mg/mL Injection, suspension Intramuscular; Intrasynovial; Soft tissue 40 mg/mL Suspension Intra-articular; Intramuscular; Intrasynovial; Soft tissue 40 mg Suspension Intra-articular; Intramuscular; Intrasynovial; Soft tissue 80 mg Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/16mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/1 Powder, for solution Intramuscular; Intravenous 1 g Powder, for solution Intramuscular; Intravenous 125 mg Powder, for solution Intramuscular; Intravenous 40 mg Powder, for solution Intramuscular; Intravenous 5 g Powder, for solution Intramuscular; Intravenous 500 mg Powder, for solution Intramuscular; Intravenous Cream Topical Lotion Topical Kit Kit Epidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical Kit Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue Injection, powder, for solution Intramuscular; Intravenous 1 g/mL Injection, powder, for solution Intramuscular; Intravenous 125 mg/mL Injection, powder, for solution Intramuscular; Intravenous 40 mg/mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/mL Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution Intravenous 40 mg/1 Kit Kit; powder Intramuscular; Intravenous 1 g Kit; powder Intramuscular; Intravenous 125 mg Kit; powder Intramuscular; Intravenous 40 mg Kit; powder Intramuscular; Intravenous 500 mg Kit; powder, for solution Intramuscular; Intravenous 1 g Kit; powder, for solution Intramuscular; Intravenous 125 mg Kit; powder, for solution Intramuscular; Intravenous 40 mg Kit; powder, for solution Intramuscular; Intravenous 500 mg Powder, for solution Intravenous 125 mg/mL Powder, for solution Intramuscular; Intravenous; Rectal 125 mg Powder, for solution Intramuscular; Intravenous; Rectal 40 mg - Prices
Unit description Cost Unit Methylprednisolone powder 96.25USD g Methylprednisolone ac powdr 40.09USD g Methylprednisolone ss 1 gm vial 31.2USD vial Solu-medrol 1 gm vial 24.43USD vial Solu-medrol (pf) 500 mg vial 20.9USD vial MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack 16.99USD disp Methylprednisolone 500 mg vial 15.6USD vial Solu-medrol 500 mg vial 12.9USD vial Depo-medrol 80 mg/ml vial 11.67USD ml Methylprednisolone 125 mg vial 10.0USD vial Methylprednisolone 80 mg/ml vial 9.12USD ml Depo-medrol 40 mg/ml vial 6.41USD ml Solu-medrol (pf) 125 mg vial 5.83USD vial Methylprednisolone 40 mg/ml vial 5.22USD ml Medrol 32 mg tablet 5.13USD tablet Methylprednisolone 32 mg tablet 4.62USD tablet Depo-medrol 20 mg/ml vial 3.78USD ml Methylprednisolone 16 mg tablet 3.17USD tablet Methylprednisolone 40 mg vial 3.0USD vial A-methapred 40 mg vial 2.36USD vial Medrol 16 mg tablet 2.28USD tablet Medrol 8 mg tablet 2.23USD tablet Methylprednisolone 8 mg tablet 1.74USD tablet Methylprednisolone 4 mg tablet 1.68USD tablet Medrol 4 mg dosepak 1.59USD each Medrol 4 mg tablet 0.99USD tablet Medrol 2 mg tablet 0.84USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 232.5 °C PhysProp water solubility 120 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 1.5 Not Available logS -2.99 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.109 mg/mL ALOGPS logP 2.06 ALOGPS logP 1.56 ChemAxon logS -3.5 ALOGPS pKa (Strongest Acidic) 12.58 ChemAxon pKa (Strongest Basic) -2.9 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 94.83 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 103.04 m3·mol-1 ChemAxon Polarizability 40.84 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9911 Blood Brain Barrier + 0.9484 Caco-2 permeable - 0.6404 P-glycoprotein substrate Substrate 0.7812 P-glycoprotein inhibitor I Non-inhibitor 0.7489 P-glycoprotein inhibitor II Non-inhibitor 0.604 Renal organic cation transporter Non-inhibitor 0.769 CYP450 2C9 substrate Non-substrate 0.8415 CYP450 2D6 substrate Non-substrate 0.9115 CYP450 3A4 substrate Substrate 0.7582 CYP450 1A2 substrate Non-inhibitor 0.9473 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9513 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9167 Ames test Non AMES toxic 0.9337 Carcinogenicity Non-carcinogens 0.9529 Biodegradation Not ready biodegradable 0.9492 Rat acute toxicity 2.0025 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9459 hERG inhibition (predictor II) Non-inhibitor 0.5985
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones show 4 more
- Substituents
- Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid show 15 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 6-methylprednisolone (CHEBI:6888) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030178)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172]
- Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711]
- Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119]
- Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542]
- Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
- Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:49